You will now be redirected to the GD3 website
PharmOptima is a proud member of Genesis Drug Discovery & Development (GD3), a fully integrated CRO providing services to support drug discovery programs of our clients from target discovery through IND filing and managing Phase I-III clinical trials.
Learn more about GD3News
-
May 4, 2025
Exhibitor at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting May 4 - 8 in Salt Lake City, Utah– Booth #: 1322
-
April 25, 2025
Exhibitor at American Association for Cancer Research (AACR)Annual Meeting April 25-30, 2025 in Chicago, Illinois– Booth #: 4913
-
April 25, 2025
Exhibitor at 13th NESACS Annual Advances in Chemical Sciences Symposium April 25, 2025 in Cambridge, Massachusetts
-
March 16, 2025
Exhibitor at Society of Toxicology (SOT) 64th Annual Meeting and ToxExpo March 16 – 20, 2025 in Orlando, Florida – Booth #: 1100
-
September 1, 2024
Genesis Drug Discovery & Development to attend Gene Therapy for Ophthalmic Disorders Summit in Boston
-
July 1, 2024
Genesis Drug Discovery & Development Appoints Madeline Farley, Ph.D. as Chief Scientific Officer of the Biochemistry and Bioanalytical Division
-
June 13, 2024
Exhibitor at the ASM-Microbe 2024 Conference in Atlanta, GA
June 13-17 -
May 9, 2024
Exhibitor at the ARVO 2024 Vision for the Future Conference in Seattle, WA
May 5-9 -
May 1, 2024
Genesis Drug Discovery & Development Attends The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Seattle
-
March 10, 2024
Exhibitor at the Society of Toxicology (SOT) 63rd Annual Meeting and ToxExpo in Salt Lake City, Utah
March 10–14 -
March 1, 2024
Genesis Drug Discovery & Development Attends Society of Toxicology Annual Meeting in Salt Lake City
-
February 1, 2024
Genesis Drug Discovery & Development Appoints Anthony Rohr, B.S., LATG, CLSSBB as Director of Business Development
-
July 1, 2023
Genesis Drug Discovery & Development Appoints Christopher Dillion, B.A., LATG, CPIA as Chief Operating Officer.
-
June 1, 2023
Genesis Drug Discovery & Development Appoints Madeline Farley, Ph.D., as Managing Member of PharmOptima
-
May 10, 2023
Genesis Drug Discovery & Development (GD3), a member of Genesis Global Group, acquires JSS Medical Research to expand its clinical services portfolio.
Read More -
January 10, 2023
Genesis Axis Acquires Organochem to Grow the Preclinical Chemistry Services Portfolio.
Read More -
October 7, 2021
Genesis Biotechnology Group Acquires BioBlocks to Grow the Preclinical Chemistry Services Portfolio of Genesis Drug Discovery & Development (GD3)
Read More -
March 4, 2021
Genesis Drug Discovery and Development acquires Integrated Analytical Solutions to add “off the shelf” PK profiling capabilities to its portfolio
Read More -
January 6, 2021
Genesis Drug Discovery and Development expands its presence in the clinical space by acquiring STATKING Clinical Services
Read More -
December 9, 2020
Genesis Biotechnology Group announces second year of CRO relationship with Yale University
Read More -
September 16, 2020
Genesis Biotechnology Group Appoints Erich E. Dagnal as Director of Mergers & Acquisitions
Read More -
September 16, 2020
Genesis Drug Discovery & Development Appoints Anthony Rohr as Chief Operating Officer
Read More -
September 16, 2020
Genesis Drug Discovery & Development Appoints Laura Sailor Veteran CRO Business Development Leader as Director of Business Development
Read More -
August 5, 2020
Genesis Biotechnology Group acquires Comparative Biosciences, Inc. (CBI) to add GLP Toxicology and Safety Pharmacology to its portfolio of Preclinical Services
Read More -
August 4, 2020
Genesis Drug Discovery & Development (GD3) Announces Appointment of Anthony Rohr, as Chief Executive Officer of PharmOptima
Read More -
November 19, 2019
Genesis Biotechnology Group acquires NEDP to grow the Preclinical Chemistry services portfolio of Genesis Drug Discovery & Development (GD3)
Read More -
September 24, 2019
Genesis Biotechnology Group® (GBG) Announces First Annual Community Fall Fest in Hamilton
Read More -
June 18, 2019
Genesis Drug Discovery & Development Expands Preclinical Contract Research Portfolio by Acquiring NexusPharma
Read More -
February 27, 2019
Genesis Drug Discovery & Development Announces Operating Agreement with Ophthy-DS, Inc.
Read More -
October 30, 2018
Genesis Biotechnology Group announces partnership with Yale University
Read More -
July 19, 2018
Genesis Drug Discovery & Development Appoints Olesia Buiakova, M.D., Ph.D., as Chief Scientific Officer
Read More -
April 29, 2018
Abstract accepted for Presentation at The Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting April 29 - May 03, 2018 in Honolulu, Hawaii
Read More -
March 1, 2017
Genesis Biotechnology Group Expands Preclinical Contract Research Portfolio by Acquiring PharmOptima
Read More